Bioquímica y Biología Molecular
Département
Isabel
Lastres Becker
Publications dans lesquelles il/elle collabore avec Isabel Lastres Becker (28)
2022
-
New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Biomolecules, Vol. 12, Núm. 9
2021
-
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Acta Neuropathologica Communications, Vol. 9, Núm. 1
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Molecular alterations in sporadic and sod1-als immortalized lymphocytes: Towards a personalized therapy
International Journal of Molecular Sciences, Vol. 22, Núm. 6, pp. 1-17
2013
-
Nrf2 participates in depressive disorders through an anti-inflammatory mechanism
Psychoneuroendocrinology, Vol. 38, Núm. 10, pp. 2010-2022
2010
-
A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice
PLoS ONE, Vol. 5, Núm. 7, pp. 1-15
2009
-
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease
GLIA, Vol. 57, Núm. 11, pp. 1154-1167
2006
-
An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments
Current Medicinal Chemistry, Vol. 13, Núm. 30, pp. 3705-3718
2005
-
Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice
Brain Research, Vol. 1046, Núm. 1-2, pp. 195-206
-
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
Neurobiology of Disease, Vol. 19, Núm. 1-2, pp. 96-107
2004
-
Involvement of the endocannabinoid system in motor disorders
Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Núm. 3, pp. 175-182
-
Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence
Brain Research, Vol. 1007, Núm. 1-2, pp. 152-159
-
Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo
NeuroReport, Vol. 15, Núm. 15, pp. 2375-2379
2003
-
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease
Journal of Neurochemistry, Vol. 84, Núm. 5, pp. 1097-1109
-
Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate
NeuroReport, Vol. 14, Núm. 6, pp. 813-816
-
Implicación del sistema cannabinoide endógeno en enfermedades neurodegenerativas extrapiramidales
Implicación del sistema cannabinoide endógeno en enfermedades neurodegenerativas extrapiramidales
-
The endocannabinoid system and Huntington's disease.
Current drug targets. CNS and neurological disorders, Vol. 2, Núm. 5, pp. 335-347
2002
-
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease
Synapse, Vol. 44, Núm. 1, pp. 23-35
-
Endocannabinoids and basal ganglia functionality
Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 66, Núm. 2-3, pp. 257-267
-
Loss of cannabinoid CB1 receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease
Neurotoxicity Research, Vol. 4, Núm. 7-8, pp. 601-608